Immune to Cancer: The CRI Blog
-
ASCO17 Recap: 7 Takeaways from the World’s Premier Clinical Cancer Conference
ASCO17’s presentations reveal that the field of immunotherapy is advancing along many fronts
-
FDA approves Keytruda combo for first-line lung cancer treatment
Patients in the U.S. who have advanced nonsquamous non-small cell lung cancer can now receive Keytruda as…
-
AACR17 Update: Checkpoint Immunotherapy Clinical Trials in Melanoma and Lung Cancer
In-depth analysis of long-term clinical trial data provides important insights for doctors treating…
-
AACR17 Update: Checkpoints, Vaccines, and the Power of Prediction
Day 3 at AACR17 highlighted the importance of immune memory and personalized approaches…
-
CICON16: The Power of Combinations
Targeting tumors from multiple angles improves our odds of success.
-
ASCO 2016 Update: The Value of Combination Immunotherapy
Activating multiple immune pathways to improve patient outcomes.
-
#AACR16 Update: Combination Therapies to Improve Anti-cancer Immune Responses
Complementary treatments can help overcome resistance to immunotherapy.
-
FDA Approval Expands Immunotherapy Options for Advanced Melanoma
Immunotherapy combinations continue to shine against melanoma.
-
Combining Different Cancer Treatments to Maximize Patient Results
As one of the most exciting areas of research in immunology, using drugs in different combinations–combination therapies–is…